Acasti Pharma Balance Sheet

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Year	2022	2021	2020	2019	2018	2017	2016	2015
Cash & Equivalents	27.88	30.34	50.94	14.24	16.87	6.28	-	2.31
Short-Term Investments	0.02	13.32	9.79	0	8.89	0	-	5.68
Cash & Cash Equivalents	27.89	43.66	60.73	14.24	25.76	6.28	0	7.99
Cash Growth	-36.12%	-28.11%	326.48%	-44.72%	310.34%	-	-	-
Receivables	0.8	0.55	0.53	0.55	1.19	0.58	-	0.3
Other Current Assets	0.6	1.07	1.11	3.68	1.02	0.39	-	0.35
Total Current Assets	29.29	45.28	62.37	18.46	27.97	7.25	-	8.65
Property, Plant & Equipment	0.57	0.57	0.09	0.15	2.11	2.15	-	0.22
Long-Term Investments	0	0	0	0	0.02	0.02	-	1.53
Goodwill and Intangibles	49.27	82.77	0	4.24	6.39	7.68	-	11.38
Other Long-Term Assets	0	0	0	0	0.42	0.42	-	0
Total Long-Term Assets	49.83	83.34	0.09	4.39	8.93	10.28	-	13.12
Total Assets	79.12	128.62	62.46	22.85	36.9	17.53	-	21.77
Accounts Payable	3.34	3.16	1.49	7.32	12.31	5.11	-	0.86
Current Debt	0.08	0.1	0.09	0.08	1.36	0	-	0
Other Current Liabilities	0	0	0	0	0	0	-	0.01
Total Current Liabilities	3.41	3.26	1.58	7.4	13.67	5.11	-	0.87
Long-Term Debt	0.41	0.19	0	0.07	0	1.23	-	0
Other Long-Term Liabilities	7.35	16.9	5.22	2.39	12.18	4.91	-	0.12
Total Long-Term Liabilities	7.76	17.09	5.22	2.46	12.18	6.14	-	0.12
Total Liabilities	11.17	20.35	6.8	9.86	25.85	11.25	-	0.99
Total Debt	0.49	0.3	0.09	0.15	1.36	1.23	-	0
Debt Growth	64.41%	243.02%	-41.50%	-89.20%	10.60%	-	-	-
Retained Earnings	-198.27	-155.84	-146.02	-126.34	-100.83	-55.25	-	-30.25
Comprehensive Income	-6.04	-6.04	-6.33	-7.89	-7.14	0	-	0
Shareholders' Equity	67.96	108.27	55.66	12.99	11.05	6.28	-	20.78
Net Cash / Debt	27.41	43.37	60.65	14.09	24.4	5.05	0	7.99
Net Cash / Debt Growth	-36.81%	-28.49%	330.32%	-42.24%	383.43%	-	-	-
Net Cash Per Share	3.69	7.06	24.54	8.00	21.57	13.85	-	35.99
Working Capital	25.88	42.02	60.79	11.07	14.3	2.13	-	7.77
Book Value Per Share	9.14	17.63	22.52	7.37	9.77	17.23	-	93.57

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).